Fred Alger Management’s Adaptimmune Therapeutics ADAP Stock Holding History

Fred Alger Management’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-25,000	Closed	-$297K	–	535
2018 Q2	$297K	Buy	+25,000	New	+$312K	﹤0.01%	379
2016 Q2	–	Sell	-23,045	Closed	-$187K	–	523
2016 Q1	$187K	Sell	23,045 -35,150	-60%	-$287K	﹤0.01%	445
2015 Q4	$702K	Buy	58,195 +16,650	+40%	+$163K	﹤0.01%	414
2015 Q3	$497K	Buy	41,545 +13,100	+46%	+$185K	﹤0.01%	435
2015 Q2	$521K	Buy	+28,445	New	+$488K	﹤0.01%	465

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Fred Alger Management's ADAP Position: Q3 2018 in Review

Fred Alger Management sold out of Adaptimmune Therapeutics (ADAP) in Q3 2018, closing a stake of 25,000 shares — an estimated $297K sold.

Fred Alger Management first reported a position in ADAP in Q2 2015 and held it in 5 quarters. The position peaked at $702K in Q4 2015. 93 funds tracked by Wall St. Rank hold ADAP as of Q3 2018.

Fred Alger Management reported no remaining Adaptimmune Therapeutics position as of Q3 2018 after selling out during the quarter.
Fred Alger Management sold 25,000 Adaptimmune Therapeutics shares in Q3 2018, an estimated $297K.
Fred Alger Management first reported a position in Adaptimmune Therapeutics in Q2 2015 and held it in 5 quarters.
Fred Alger Management's Adaptimmune Therapeutics position peaked at $702K in Q4 2015.
93 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2018.

Based on Fred Alger Management's 13F filing for Q3 2018, filed 14 Nov 2018.